Literature DB >> 7804022

Effects of menstrual phase on intake of nicotine, caffeine, and alcohol and nonprescribed drugs in women with late luteal phase dysphoric disorder.

J L Marks1, C S Hair, S C Klock, B E Ginsburg, C S Pomerleau.   

Abstract

To investigate the possibility that cigarette smoking and other drug use are affected by menstrual phase in smokers with Late Luteal Phase Dysphoric Disorder (LLPDD), we examined daily diaries rating menstrual symptomatology, smoking, alcohol and nonprescription drug use, and caffeine intake in nine female smokers meeting criteria for LLPDD. Menstrual symptomatology peaked during the premenstrual phase. Smoking, alcohol, and nonprescription drug intake were increased during menses; caffeine intake was unaffected by phase. No systematic intrasubject correlation between symptomatology and smoking was detected. It was concluded that in women with LLPDD, smoking and alcohol and nonprescription drug intake appear to vary as a function of menstrual phase. The lack of intrasubject correlations between symptomatology and intake, and the failure of peak intake to coincide with peak symptomatology, however, indicate that these effects cannot be explained simply as "self-medication" of acute episodes of dysphoric mood.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7804022     DOI: 10.1016/s0899-3289(94)90265-8

Source DB:  PubMed          Journal:  J Subst Abuse        ISSN: 0899-3289


  18 in total

1.  Menstrual cycle and cue reactivity in women smokers.

Authors:  Kevin M Gray; Stacia M DeSantis; Matthew J Carpenter; Michael E Saladin; Steven D LaRowe; Himanshu P Upadhyaya
Journal:  Nicotine Tob Res       Date:  2009-12-08       Impact factor: 4.244

2.  The relationship between alcohol consumption and menstrual cycle: a review of the literature.

Authors:  Haley A Carroll; M Kathleen B Lustyk; Mary E Larimer
Journal:  Arch Womens Ment Health       Date:  2015-08-21       Impact factor: 3.633

3.  Menstrual cycle phase, alcohol consumption, alcohol cravings, and mood among women in outpatient treatment for alcohol use disorder.

Authors:  Jumi Hayaki; Cathryn G Holzhauer; Elizabeth E Epstein; Sharon Cook; Ayorkor Gaba; Ava C Lorenzo; Barbara S McCrady
Journal:  Psychol Addict Behav       Date:  2020-04-06

4.  Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion.

Authors:  Carolyn M Mazure; Benjamin Toll; Sherry A McKee; Ran Wu; Stephanie S O'Malley
Journal:  Drug Alcohol Depend       Date:  2010-09-15       Impact factor: 4.492

Review 5.  Systematic and meta-analytic review of research examining the impact of menstrual cycle phase and ovarian hormones on smoking and cessation.

Authors:  Andrea H Weinberger; Philip H Smith; Sharon S Allen; Kelly P Cosgrove; Michael E Saladin; Kevin M Gray; Carolyn M Mazure; Cora Lee Wetherington; Sherry A McKee
Journal:  Nicotine Tob Res       Date:  2015-04       Impact factor: 4.244

6.  Influence of phase-related variability in premenstrual symptomatology, mood, smoking withdrawal, and smoking behavior during ad libitum smoking, on smoking cessation outcome.

Authors:  Sharon S Allen; Alicia M Allen; Cynthia S Pomerleau
Journal:  Addict Behav       Date:  2008-08-27       Impact factor: 3.913

7.  Circadian patterns of ad libitum smoking by menstrual phase.

Authors:  Alicia M Allen; Marc Mooney; Rima Chakraborty; Sharon S Allen
Journal:  Hum Psychopharmacol       Date:  2009-08       Impact factor: 1.672

Review 8.  Hormones, nicotine, and cocaine: clinical studies.

Authors:  Nancy K Mello
Journal:  Horm Behav       Date:  2009-10-14       Impact factor: 3.587

9.  Cigarette smoking and the development of premenstrual syndrome.

Authors:  Elizabeth R Bertone-Johnson; Susan E Hankinson; Susan R Johnson; Joann E Manson
Journal:  Am J Epidemiol       Date:  2008-08-13       Impact factor: 4.897

Review 10.  Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.